MX2019004222A - Protective effect of dmpc, dmpg, dmpc/dmpg, egpg, lysopg and lysopc against drugs that cause channelopathies. - Google Patents

Protective effect of dmpc, dmpg, dmpc/dmpg, egpg, lysopg and lysopc against drugs that cause channelopathies.

Info

Publication number
MX2019004222A
MX2019004222A MX2019004222A MX2019004222A MX2019004222A MX 2019004222 A MX2019004222 A MX 2019004222A MX 2019004222 A MX2019004222 A MX 2019004222A MX 2019004222 A MX2019004222 A MX 2019004222A MX 2019004222 A MX2019004222 A MX 2019004222A
Authority
MX
Mexico
Prior art keywords
dmpg
dmpc
egpg
lysopg
channelopathies
Prior art date
Application number
MX2019004222A
Other languages
Spanish (es)
Inventor
Majeed Muhammed
Helson Lawrence
M Shopp George
Bouchard Annie
Original Assignee
Signpath Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US15/297,901 external-priority patent/US10449193B2/en
Application filed by Signpath Pharma Inc filed Critical Signpath Pharma Inc
Publication of MX2019004222A publication Critical patent/MX2019004222A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dispersion Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The present invention includes compositions and methods for preventing one or more cardiac channelopathies or conditions resulting from irregularities or alterations in cardiac patterns caused by an active agent or a drug in a human or animal subject comprising: an amount of a phosphatidylglycerol adapted for oral administration effective to reduce or prevent one or more cardiac channelopathies or conditions resulting from irregularities or alterations in cardiac patterns caused by the active agent or drug, and one or more organoleptic, thixotropic, or both organoleptic and thixotropic agents.
MX2019004222A 2016-10-19 2017-10-19 Protective effect of dmpc, dmpg, dmpc/dmpg, egpg, lysopg and lysopc against drugs that cause channelopathies. MX2019004222A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15/297,901 US10449193B2 (en) 2011-06-03 2016-10-19 Protective effect of DMPC, DMPG, DMPC/DMPG, lysoPG and lysoPC against drugs that cause channelopathies
PCT/US2017/057446 WO2018075801A1 (en) 2016-10-19 2017-10-19 Protective effect of dmpc, dmpg, dmpc/dmpg, egpg, lysopg and lysopc against drugs that cause channelopathies

Publications (1)

Publication Number Publication Date
MX2019004222A true MX2019004222A (en) 2019-06-10

Family

ID=62019674

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019004222A MX2019004222A (en) 2016-10-19 2017-10-19 Protective effect of dmpc, dmpg, dmpc/dmpg, egpg, lysopg and lysopc against drugs that cause channelopathies.

Country Status (8)

Country Link
EP (1) EP3528848A4 (en)
JP (1) JP2019531309A (en)
KR (1) KR20190042775A (en)
CN (2) CN109843331A (en)
AU (2) AU2017345473A1 (en)
CA (1) CA3039596C (en)
MX (1) MX2019004222A (en)
WO (1) WO2018075801A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7300394B2 (en) 2017-01-17 2023-06-29 ヘパリジェニックス ゲーエムベーハー Protein kinase inhibition to promote liver regeneration or reduce or prevent hepatocyte death
ES2960541T3 (en) * 2017-10-19 2024-03-05 Signpath Pharma Inc Liquid compositions for peroral use comprising phosphatidylglycerol derivatives and thixotropic excipients for treating cardiac channelopathies caused by pharmacological agents

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8618847D0 (en) * 1986-08-01 1986-09-10 Smith Kline French Lab Pharmaceutical formulations
GB9224855D0 (en) * 1992-11-27 1993-01-13 Smithkline Beecham Plc Pharmaceutical compositions
UA80682C2 (en) * 2001-08-06 2007-10-25 Pharmacia Corp Orally deliverable stabilized oral suspension formulation and process for the incresaing physical stability of thixotropic pharmaceutical composition
US20050233970A1 (en) * 2004-03-23 2005-10-20 Praecis Pharmaceuticals, Inc. Methods for treating long QT syndrome
JPWO2008093848A1 (en) * 2007-02-02 2010-05-20 サンスター株式会社 Inflammatory marker reducing composition containing phosphatidylcholine
JP5638204B2 (en) * 2009-05-29 2014-12-10 国立大学法人 岡山大学 Liposome preparation for oral administration and production method thereof
WO2012094033A1 (en) * 2011-01-05 2012-07-12 Livon Laboratories Methods of making liposomes, liposome compositions made by the methods, and methods of using the same
CA2836904C (en) * 2011-06-03 2019-09-24 Signpath Pharma Inc. Liposomal mitigation of drug-induced long qt syndrome and potassium delayed-rectifier current
EP2814497A4 (en) * 2012-02-16 2015-12-09 Vascular Biogenics Ltd Methods for treating psoriasis and vascular inflammation
WO2014036534A1 (en) * 2012-08-31 2014-03-06 University Of North Texas Health Science Center Curcumin-er, a liposomal-plga sustained release nanocurcumin for minimizing qt prolongation for cancer therapy
EP3207931A3 (en) * 2014-06-03 2017-12-20 Signpath Pharma Inc. Protective effect of dmpc, dmpg, dmpc/dmpg, egpg, lysopg and lysopc against drugs that cause channelopathies

Also Published As

Publication number Publication date
WO2018075801A1 (en) 2018-04-26
CN109843331A (en) 2019-06-04
EP3528848A1 (en) 2019-08-28
AU2020267307A1 (en) 2020-12-10
EP3528848A4 (en) 2020-07-15
JP2019531309A (en) 2019-10-31
CA3039596C (en) 2022-04-12
KR20190042775A (en) 2019-04-24
AU2017345473A1 (en) 2019-04-18
CN111481508A (en) 2020-08-04
CA3039596A1 (en) 2018-04-26

Similar Documents

Publication Publication Date Title
EP3207931A3 (en) Protective effect of dmpc, dmpg, dmpc/dmpg, egpg, lysopg and lysopc against drugs that cause channelopathies
MX2019005141A (en) Protective effect of dmpc, dmpg, dmpc/dmpg, lysopg and lysopc against drugs that cause channelopathies.
PH12019502058A1 (en) Farnesoid x receptor agonists and uses thereof
PH12018500586A1 (en) Farnesoid x receptor agonists and uses thereof
MX2016000364A (en) Methods for treating or preventing ophthalmological conditions.
MX2017014338A (en) Targeted selection of patients for treatment with cortistatin derivatives.
EA201691454A1 (en) COMPOSITIONS OF PRIDOPIDININE MODIFIED SHIPPING
JOP20190281A1 (en) N2,n4-diphenylpyrimidin-2,4-diamine derivative, method for preparing same, and pharmaceutical composition containing same as active ingredient for prevention or treatment of cancer
PH12018502109A1 (en) Medicine obtained by combining fxr agonist and arb
MX2016010179A (en) Donepezil compositions and method of treating alzheimer's disease.
PH12017502376A1 (en) Oral solid formulation containing irinotecan and method of preparing the same
MX2022011372A (en) Zinc-î³-pga compositions and methods for treating cancer.
PH12016502233A1 (en) (s)-pirlindole or its pharmaceutically acceptable salts for use in medicine
MX2019001467A (en) Combination of glucagon receptor antagonists and pi3k pathway inhibitors for the treatment of cancer.
IL274456A (en) Inhibitor of the expression of cancer-promoting factors, screening method for active ingredient thereof, expression cassette useful in said method, diagnostic drug, and diagnostic method
CO2017003263A2 (en) Pharmaceutical composition based on anamorelin having activity on cachexia caused by cancer
MX2019004222A (en) Protective effect of dmpc, dmpg, dmpc/dmpg, egpg, lysopg and lysopc against drugs that cause channelopathies.
NZ602807A (en) 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1h-benzimidazol-2-yl]-1h-quinolin-2-one and an mtor inhibitor
MX2017014776A (en) Pharmaceutical combination of everolimus with dactolisib.
MX2023007136A (en) Protective effect of dmpc, dmpg, dmpc/dmpg, lysopg and lysopc against drugs that cause channelopathies.
MX2023006235A (en) Compositions for drug delivery and methods of use thereof.
MX2020010243A (en) Oral compositions and methods for animals.
ZA202104167B (en) Compounds for use in the treatment of parkinson's disease
RU2014107146A (en) METHOD FOR PREVENTING A CARCINOGENIC EFFECT OF DIETHYLNITROSAMINE IN EXPERIMENTAL ANIMALS
UA82584U (en) Method for treating vestibular migraine and comorbid dizziness syndrome in women with perimenopausal vestibular dysfunction